Form D · Pharmaceuticals

Aqur Biosciences, Inc.

Westlake Village, CA · CIK 0002094075

Offering snapshot reported Sep 18, 2026 · SEC filing

Reported sold: $1.5M
Investors reported: 7
Minimum accepted: $0
First sale: Sep 3, 2026

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Sep 18, 2026	Initial	$1,500,000	No comparison	7	SEC filing

Offering details

Securities: Equity, Option to acquire, Security to be acquired
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-598066

Sale of Series B Convertible Preferred Stock and accompanying warrants in a private placement to accredited investors

Roth Capital Partners, LLC was paid a fixed fee of $125,000 for advisory services related to the offering, but will not receive any sales commissions, finders' fees or other fees contingent upon subscriptions.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Roth Capital Partners, LLC	15407

Source: Form D, filed Sep 18, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Michel F Denarie	Executive
Michael A Fole	Executive
James Hess Leach	Executive
Tomi K Sawyer	Executive
Jeffrey B Wolin	Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

2829 Townsgate Road Suite 100
Westlake Village, CA, 91361
Phone: 818-698-1006